Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Medisorb Naltrexone in Alcohol/Opioid Dependence
NCT01218997Phase 3Completed
- Sponsor
- Alkermes
- Start
- Aug 2003
- Primary completion
- Mar 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of naltrexone in alcohol dependence and opioid use disorder (OUD) (2 arms), sponsored by Alkermes. Primary endpoint: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study at 1 year. Started Aug 2003; status: completed.
02
Drugs
naltrexone
03
Conditions
alcohol dependenceopioid use disorder (OUD)
Beyond the preview
Go deeper on NCT01218997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218997.